JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Pliant Therapeutics Inc

Chiusa

1.68 1.82

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.62

Massimo

1.71

Metriche Chiave

By Trading Economics

Entrata

-6.4M

-56M

Dipendenti

171

EBITDA

-10M

-59M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+57.65% upside

Dividendi

By Dow Jones

Utili prossimi

12 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

6.8M

104M

Apertura precedente

-0.14

Chiusura precedente

1.68

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Pliant Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 ago 2025, 17:49 UTC

I principali Market Mover

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 ago 2025, 17:18 UTC

I principali Market Mover

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 ago 2025, 16:25 UTC

Utili

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 ago 2025, 23:50 UTC

Discorsi di Mercato

Nikkei May Rise as Yen Weakens -- Market Talk

11 ago 2025, 23:42 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

11 ago 2025, 23:42 UTC

Discorsi di Mercato

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 ago 2025, 23:36 UTC

Discorsi di Mercato

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 ago 2025, 23:32 UTC

Discorsi di Mercato

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 ago 2025, 23:02 UTC

Discorsi di Mercato

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 ago 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

11 ago 2025, 20:37 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 ago 2025, 20:37 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 ago 2025, 20:37 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 ago 2025, 20:22 UTC

Utili

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 ago 2025, 20:22 UTC

Utili

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 ago 2025, 20:22 UTC

Utili

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 ago 2025, 20:22 UTC

Utili

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 ago 2025, 20:22 UTC

Utili

Exodus Movement 2Q Rev $25.8M >EXOD

11 ago 2025, 20:14 UTC

Discorsi di Mercato

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 ago 2025, 19:12 UTC

Discorsi di Mercato

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 ago 2025, 18:56 UTC

Discorsi di Mercato

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 ago 2025, 18:31 UTC

Discorsi di Mercato

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 ago 2025, 17:43 UTC

Discorsi di Mercato

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 ago 2025, 17:28 UTC

Discorsi di Mercato

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 ago 2025, 17:16 UTC

Discorsi di Mercato

Commodity Longs Fall to 11-Month Low -- Market Talk

11 ago 2025, 16:42 UTC

Acquisizioni, Fusioni, Takeovers

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 ago 2025, 16:27 UTC

Acquisizioni, Fusioni, Takeovers

BBVA Says Sabadell Offer Remains in Effect

11 ago 2025, 16:26 UTC

Acquisizioni, Fusioni, Takeovers

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 ago 2025, 16:25 UTC

Acquisizioni, Fusioni, Takeovers

Banco de Sabadell Announced TSB Sale on July 1

11 ago 2025, 16:25 UTC

Acquisizioni, Fusioni, Takeovers

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Confronto tra pari

Modifica del prezzo

Pliant Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

57.65% in crescita

Previsioni per 12 mesi

Media 2.68 USD  57.65%

Alto 4 USD

Basso 1.7 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Pliant Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

6 ratings

1

Acquista

5

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.43 / 1.6Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Weak Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.